Samsung Biologics Bids 1.46 Billion Francs for PolyPeptide in Record Korean Deal

The all-cash offer values the Swiss peptide manufacturer at 44.31 francs per share as Seoul’s largest contract developer targets obesity drug capacity.

Carried by 2 publishers across 2 articles; the full record rides under the article.

Truth Foundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.